Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...
In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...
Pfizer Investigational Site, Dubai, United Arab Emirates
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
University of Iowa, Iowa City, Iowa, United States
Moses Cone, Greensboro, North Carolina, United States
The Zucker Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, New York, United States
Staten Island University Hospital, Staten Island, New York, United States
Emory University School of Medicine, Atlanta, Georgia, United States
Northwestern Medical School Department of Psychiatry, Chicago, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.